Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 17%
Buy 22%
Hold 50%
Sell 6%
Strong Sell 6%

Bulls say

Zimmer Biomet Holdings has demonstrated a strong turnaround in its business, highlighted by a 11.3% increase in Bone Cement and Surgical sales driven by robust placements of the Rosa system. The company has consistently achieved growth that is either in-line with or surpasses its peers over multiple quarters, supported by healthy orthopedic market conditions and recent mergers and acquisitions. Additionally, the performance of its Knee segment, which grew 5.3% globally, indicates successful product adoption, especially within the Persona OsseoTi offerings, showcasing the potential for further operating leverage from ongoing restructuring initiatives.

Bears say

Zimmer Biomet Holdings (ZBH) faces a negative outlook primarily due to stagnant average selling prices (ASP) expected for FY25 and reduced growth estimates across revenue segments, with projected organic growth at only 3.1% for FY26. The company's knee growth has underperformed compared to its peers, and significant execution challenges have led to adjustments in operating margin forecasts, indicating potential difficulties in maintaining competitive market positioning. Additionally, risks such as market share losses, manufacturing issues, slower commercialization of new products like ROSA, and delayed new product introductions further contribute to a cautious sentiment regarding ZBH's financial performance.

ZBH has been analyzed by 18 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 22% recommend Buy, 50% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Hold based on their latest research and market trends.

According to 18 analysts, ZBH has a Hold consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.